The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Open accessAbstract
The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL). Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days rest, and group 3 received vorinostat 300 mg twice daily for 14 days with 7 days rest followed by 200 mg twice daily. Treatment continued until disease progression or intolerable toxicity. The primary objective was to determine the complete and partial response (PR) rate. Time to response (TTR), time to progressive disease (TTP), response duration (DOR), pruritus relief, and safety were determined. Thirty-three patients who had received a median of 5 prior therapies were enrolled. Eight patients achieved a PR, including 7 with advanced disease and 4 with Sézary syndrome. The median TTR, DOR, and TTP for responders were 11.9, 15.1, and 30.2 weeks, respectively. Fourteen of 31 evaluable patients had pruritus relief. The most common drug-related AEs were fatigue, thrombocytopenia, diarrhea, and nausea. The most common grade 3 or 4 drug-related AEs were thrombocytopenia and dehydration. Vorinostat demonstrated activity in heavily pretreated patients with CTCL. The 400 mg daily regimen had the most favorable safety profile and is being further evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various KDAC inhibitors [19] have been approved by the FDA such as vorinostat [20] (commonly known as SAHA) and romidepsin [21], but there are currently no approved KAT inhibitors [22–24].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SAHA exemplifies broad-spectrum inhibition (Marks et al., 2001; Duvic et al., 2007)”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Duvic et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 4×
“Thrombocytopenia 20 (54) 10 (27) 3 (8) 4 (11) 3 (8)”
InfluentialSelf-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 1×
“All patients 4/13 (31) 9.1, 61.4 1/11 (9) 0.2, 41.3 3/9 (33) 7.5, 70.1 8/33 (24) 11.1, 42.3 Stage less than IIB* 0/2 (0) 0.0, 84.2 0/1 (0) 0.0, 97.5 1/2 (50) 1.3, 98.7 1/5 (20) 0.5, 71.6 Stage at least IIB† 4/11 (36) 10.9, 69.2 1/10 ( 10 ) 0.3, 44.5 2/7 (29) 3.7, 71.0 7/28 (25) 10.7, 44.9 Sezary syndrome 1/3 (33) 0.8,…”
InfluentialTreatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., Vonderheid, E., Knobler, R., Wolff, K., Plewig, G., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702053160603 · Cited by 1,199
Embryonic Stem Cell-Specific MicroRNAs
Houbaviy, H. B., Murray, M. F., & Sharp, P. A. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00227-2 · Cited by 1,129
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905 · cited 3×
“Thrombocytopenia 20 (54) 10 (27) 3 (8) 4 (11) 3 (8)”
Self-citationA small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes
Kent, O. A., & Mendell, J. T. (2006) · Oncogene · doi:10.1038/sj.onc.1209913 · Cited by 720
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706 · cited 1×
“Dehydration 6 (16) 1 (3) 2 (5) 1 (3) 2 (5)”
Self-citationCell-type-specific signatures of microRNAs on target mRNA expression
Sood, P., Krek, A., Zavolan, M., Macino, G., & Rajewsky, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511045103 · Cited by 650
Cited by
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
“A milestone in therapy using agents that modify the epigenome is the recent FDA approval of vorinostat (Zolinza; Merck) and romidepsin (Istodax; Celgene) for their remarkable efficacy in cutaneous T cell lymphom”
BackgroundHaberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
“HDAC inhibitors from multiple chemical classes have entered clinical trials, and SAHA (marketed as Vorinostat, brand name Zolinza) has been approved for treatment of cutaneous manifestations of advanced, refractory T-cell lymphoma in a select group of patient”
BackgroundHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“Vorinostat is the first of the new HDACi to be approved by Food and Drug Administration for the clinical use in cancer patients, namely the treatment of cutaneous T-cell lymphoma (CTCL) (Duvic et al., 2007; Garber, 2007).”
BackgroundInfluentialNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
“The most successful clinical application of HDACis has been the use of vorinostat and romidepsin against refractory cutaneous and peripheral T cell lymphoma (52–55).”
Background
Metadata
- Authors
- Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., & Frankel, S. R.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Duvic, Madeleine
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-09-07
- Volume
- 109
- Issue
- 1
- Pages
- 31-39
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC1785068
- OpenAlex
- W2071115015
- Cited by
- 1,141
- References
- 49
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 25 · 2023: 41 · 2022: 34 · 2021: 51 · 2020: 62 · 2019: 49 · 2018: 47 · 2017: 51 · 2016: 77 · 2015: 92 · 2014: 59 · 2013: 65 · 2012: 74
- FWCI
- 71.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K24CA086815)
- Topics
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- vorinostat, cutaneous T-cell lymphoma, histone deacetylase inhibitors, Sézary syndrome, pruritus relief, treatment response, drug safety, thrombocytopenia, dosing regimen
- MeSH terms
- Vorinostat, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dehydration, Fatigue, Female, Gastrointestinal Diseases, Humans, Hydroxamic Acids, Lymphocytes, Male, Middle Aged, Pruritus, Remission Induction, Sezary Syndrome, Skin, Thrombocytopenia, Lymphoma, T-Cell, Cutaneous, Salvage Therapy, Treatment Outcome, Disease Progression, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). https://app.cochat.ai/papers/10.1182/blood-2006-06-025999
- The paper
- Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., & Frankel, S. R. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. https://doi.org/10.1182/blood-2006-06-025999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.